Minerva Neurosciences Company Profile (NASDAQ:NERV)

Analyst Ratings

Consensus Ratings for Minerva Neurosciences (NASDAQ:NERV) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.00 (49.25% upside)

Analysts' Ratings History for Minerva Neurosciences (NASDAQ:NERV)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Jefferies GroupReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016JMP SecuritiesBoost Price Target$10.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2015Robert W. BairdSet Price TargetBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Minerva Neurosciences (NASDAQ:NERV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.36)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.41)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.46)($0.40)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($2.30)($1.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.38)($2.55)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Minerva Neurosciences (NASDAQ:NERV)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.20)($0.20)($0.20)
Q4 20161($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Minerva Neurosciences (NASDAQ:NERV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Minerva Neurosciences (NASDAQ:NERV)
DateHeadline
07/21/16 05:41 PMMinerva Neurosciences Incorporated (NASDAQ:NERV) Short Interest Decreased By 5.62% - Consumer Eagle
07/21/16 08:15 AMA Reversal for Minerva Neurosciences Inc Is Not Near. The Stock Rises Again - Consumer Eagle
07/15/16 10:12 AMIs Minerva Neurosciences Inc a Sell? The Stock Declines Again - Press Telegraph
07/14/16 09:01 AMInsiders Increasing Positions in: Minerva Neurosciences, Inc. (NASDAQ:NERV) - Press Telegraph
07/14/16 09:01 AMStrong Sell Calls For Minerva Neurosciences, Inc (NASDAQ:NERV) At 0 - Investor Newswire
07/08/16 05:30 PMMinerva Neurosciences, Inc. Stock Momentum Hits Strength - CML News
07/07/16 08:20 AMMinerva Neurosciences, Inc (NASDAQ:NERV) Expected to Reach Highs Of $17 - Investor Newswire
07/07/16 08:20 AMWhat's Next for Minerva Neurosciences Inc After Today's Huge Increase? - Engelwood Daily
07/06/16 10:01 AMStock Tracking Down This Month; Investor Alert on Minerva Neurosciences, Inc. (NASDAQ:NERV) - Engelwood Daily
07/02/16 08:10 AMMinerva Neurosciences, Inc (NERV) Current Analyst Ratings - Fiscal Standard
07/01/16 08:13 AMActive Stocks to Watch: Himax Technologies, Inc. (NASDAQ:HIMX), Minerva Neurosciences, Inc. (NASDAQ:NERV ... - KC Register
06/29/16 08:12 AMMinerva Neurosciences Set to Join Russell 3000® and Russell 2000® Indexes - GlobeNewswire (press release)
06/27/16 07:41 AMMinerva Neurosciences Set to Join Russell 3000® and Russell 2000® Indexes - [at noodls] - WALTHAM, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced that the Company has been added to the Russell 3000 ...
06/23/16 08:07 AMStrong Buy Calls Count For Minerva Neurosciences, Inc (NASDAQ:NERV) At 1 - Investor Newswire
06/22/16 05:18 PMMinerva Neurosciences, Inc. (NasdaqGM:NERV) Upside Stock Momentum at EXTREME Strength - CML News
06/22/16 10:08 AMBiotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma - PR Newswire (press release)
06/17/16 05:12 PMMinerva Neurosciences Inc. to present in New York
06/17/16 05:12 PMMINERVA NEUROSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/17/16 03:07 PMMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/17/16 08:10 AMMinerva Neurosciences Inc. announces pricing - MetroWest Daily News
06/17/16 08:10 AMMinerva Neurosciences Inc. to present in New York ... - MetroWest Daily News
06/16/16 09:38 AMMinerva Neurosciences Inc. announces pricing
06/15/16 05:21 PMMinerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016 - Nasdaq
06/15/16 09:58 AMMINERVA NEUROSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
06/14/16 05:07 PMMinerva Neurosciences Announces Pricing of Public Offering of Common Stock - Nasdaq
06/14/16 03:34 PMMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S -
06/14/16 03:29 PMMinerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016 - [at noodls] - WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central ...
06/14/16 10:12 AMBRIEF-Minerva neurosciences announces proposed public offering of common stock - Reuters
06/14/16 08:29 AMMinerva Neurosciences Announces Pricing of Public Offering of Common Stock - [at noodls] - WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of ...
06/14/16 08:05 AM9:05 am Minerva Neurosciences prices ~5.26 mln common stock offering at $9.50/share -
06/13/16 03:19 PMMinerva Neurosciences Announces Proposed Public Offering of Common Stock - [at noodls] - WALTHAM, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common ...
06/09/16 08:20 AMYesterday Stock's Trend Overview: Minerva Neurosciences, Inc (NASDAQ:NERV) , Keryx Biopharmaceuticals, Inc ... - Street Updates
06/06/16 05:19 PMAnalyst Recommendations on These Hot Stocks: Minerva Neurosciences, Inc. (NASDAQ:NERV), Calpine Corp. (NYSE ... - Beacon Chronicle
06/06/16 09:04 AMHealthcare Stocks to watch: Neovasc Inc. (NASDAQ:NVCN) , Minerva Neurosciences, Inc (NASDAQ:NERV) - Is stories
06/06/16 08:18 AMMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/04/16 08:16 AMHealthcare Stock to Lookout: Minerva Neurosciences Inc (NASDAQ:NERV) - The Point Review
06/03/16 05:54 PMAnalyst Recommendations on These Stocks: Allergan plc (NYSE:AGN), Minerva Neurosciences, Inc. (NASDAQ:NERV) - Beacon Chronicle
06/03/16 08:15 AMHealthcare Stocks in the Spotlight: Minerva Neurosciences Inc(NASDAQ:NERV), Novavax, Inc.(NASDAQ:NVAX) - NYSE Journal (press release) - Healthcare Stocks in the Spotlight: Minerva Neurosciences Inc(NASDAQ:NERV), Novavax, Inc.(NASDAQ:NVAX)NYSE Journal (press release)On Thursday, Shares of Minerva Neurosciences Inc (NASDAQ:NERV), added 3.02% and closed at $14.33 in the last trading session. The last trading range of the stock ranges between $13.32 and $15.84. Minerva Neurosciences, Inc. (NERV), a clinical-stage ...and more »
06/03/16 08:15 AMEarnings Analysis to see: Minerva Neurosciences, Inc. (NASDAQ:NERV), Equity Residential (NYSE:EQR) - Beacon Chronicle - Earnings Analysis to see: Minerva Neurosciences, Inc. (NASDAQ:NERV), Equity Residential (NYSE:EQR)Beacon ChronicleMinerva Neurosciences, Inc. (NASDAQ:NERV) currently has High Price Target of $17. The Low and Mean Price Targets are $17 and $17 respectively. These price targets are a consensus analysis of 2 brokers. When having a look at Recommendation Trends ...and more »
06/03/16 08:15 AMAnalysts Suggestion Alert: Minerva Neurosciences, Inc (NASDAQ:NERV) , Alexion Pharmaceuticals, Inc. (NASDAQ ... - Street Updates - Is storiesAnalysts Suggestion Alert: Minerva Neurosciences, Inc (NASDAQ:NERV) , Alexion Pharmaceuticals, Inc. (NASDAQ ...Street UpdatesMinerva Neurosciences, Inc (NASDAQ:NERV) accumulated +3.02%, closing at $14.33 after floating between $13.32 and $15.84. The company has market capitalization of $400.41M. It has twelve month low of $3.45 and twelve month high of $15.84.Healthcare Stocks within Traders Concentration: Minerva Neurosciences, Inc (NASDAQ:NERV) , Centene Corporation ...Is storiesall 3 news articles »
06/02/16 05:47 PMHealthcare Bulls: Galena Biopharma Inc (NASDAQ:GALE), Minerva Neurosciences, Inc. (NASDAQ:NERV), Pfizer Inc ... - KC Register - Healthcare Bulls: Galena Biopharma Inc (NASDAQ:GALE), Minerva Neurosciences, Inc. (NASDAQ:NERV), Pfizer Inc ...KC RegisterOn Wednesday Galena Biopharma Inc (NASDAQ:GALE) share price closed at $2.16. Galena Biopharma Inc (NASDAQ:GALE) is -9.62% away from its 52 week high and its 52 week range is $0.59 – 2.39. Galena Biopharma Inc (NASDAQ:GALE) announced ...and more »
06/02/16 12:00 PMMinerva Neurosciences, Inc. :NERV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/02/16 08:19 AMMinerva Neurosciences Continues To Rally, Up 300% In A Week - Benzinga - Minerva Neurosciences Continues To Rally, Up 300% In A WeekBenzingaMinerva Neurosciences Inc NERV 13.09% shares are trading higher by $1.60 (15 percent) at $13.90 in Wednesday's session. It has backed off its intra-day and all-time high made earlier in the session at $14.54. The issue continues to benefit from meeting ...
06/02/16 08:19 AMRock Creek Pharmaceuticals (OTCMKTS:RCPI) & Minerva Neurosciences Inc (NASDAQ:NERV) Healthcare Trader's ... - Wall Street 24 - Small Cap Exclusive (press release)Rock Creek Pharmaceuticals (OTCMKTS:RCPI) & Minerva Neurosciences Inc (NASDAQ:NERV) Healthcare Trader's ...Wall Street 24On Wednesday, Shares of Rock Creek Pharmaceuticals Inc (OTCMKTS:RCPI) gained 3.31% to $0.0187. The share price is trading in a range of $0.02 – $0.03. The stock exchanged hands with 51.34 Million shares contrast to its average daily volume of 5.22 ...Minerva Neurosciences Inc (NASDAQ:NERV) Makes Progress with Antidepressant Drug CandidateSmall Cap Exclusive (press release)Analyst Price Target Recommendation about two Stocks: Shire plc (NASDAQ:SHPG), Minerva Neurosciences, Inc ...WsNews 4investorsall 6 news articles »
06/01/16 05:54 PMMinerva Neurosciences Inc (NASDAQ:NERV): Our Buy Was At $11.85, Making Big Profit In Short Time - US Market Buzz - Minerva Neurosciences Inc (NASDAQ:NERV): Our Buy Was At $11.85, Making Big Profit In Short TimeUS Market BuzzWell, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term ...and more »
06/01/16 05:54 PMSmall Cap Volatile Stocks: Jupai Holdings Limited (NYSE:JP), Minerva Neurosciences, Inc. (NASDAQ:NERV), iCAD ... - KC Register - Small Cap Volatile Stocks: Jupai Holdings Limited (NYSE:JP), Minerva Neurosciences, Inc. (NASDAQ:NERV), iCAD ...KC RegisterMinerva Neurosciences, Inc. (NASDAQ:NERV) traded 3.51 Million shares and its share price advanced 8.66% to close at $12.30. Company has 0.70% insider ownership. Minerva Neurosciences, Inc. (NASDAQ:NERV) quarterly performance is 146.00% while ...Jupai Holdings Limited (NYSE:JP) Shoot Up 13.49%: Flexion Therapeutics, Inc. (NASDAQ:FLXN), JP Energy Partners ...Benchmark Monitorall 4 news articles »
06/01/16 05:54 PMMinerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016 - Nasdaq - Market ExclusiveMinerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016NasdaqWALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today ...Did Minerva Neurosciences Inc (NASDAQ:NERV) Deserve its End of Week Gains?Market ExclusiveEarnings Trend of the Stock: Minerva Neurosciences, Inc. (NASDAQ:NERV), The Hartford Financial Services Group, Inc ...Beacon ChronicleMinerva Neurosciences Inc. (NASDAQ:NERV) announced positive top-line results from a phase IIa trialInside TradeRisers & Fallers -Street Updates -Zergwatchall 22 news articles »
06/01/16 08:18 AMHave a look at Analyst Actions: Boston Scientific Corporation (NYSE:BSX) , Minerva Neurosciences, Inc (NASDAQ ... - Street Updates - Have a look at Analyst Actions: Boston Scientific Corporation (NYSE:BSX) , Minerva Neurosciences, Inc (NASDAQ ...Street UpdatesOn 5/31/2016, Boston Scientific Corporation (NYSE:BSX) ended trading session higher at $22.71 with +0.58%. The company traded a volume of 9.15 million shares as comparison to average volume of 9.51 million shares. During the 52 –week period, the ...and more »
06/01/16 07:33 AMMinerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016 - [at noodls] - WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central ...
05/31/16 05:39 PMWatch List - Novavax, (NASDAQ:NVAX), Minerva Neurosciences, (NASDAQ:NERV) - Hot Stocks Point - Hot Stocks PointWatch List - Novavax, (NASDAQ:NVAX), Minerva Neurosciences, (NASDAQ:NERV)Hot Stocks PointNovavax, Inc. (NASDAQ:NVAX) gained 4.27% and closed in the last trading session at $5.86. The company's price range for the trading day was $5.58 to $5.86. The company's Market capitalization is $1.65B with the total Outstanding Shares of 270.78M. The ...and more »

Social

About Minerva Neurosciences

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NERV
  • CUSIP:
Key Metrics:
  • Previous Close: $11.39
  • 50 Day Moving Average: $10.56
  • 200 Day Moving Average: $7.16
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $318.26M
  • Beta: 1.94
  • Current Year EPS Consensus Estimate: $N/A EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
Minerva Neurosciences (NASDAQ:NERV) Chart for Tuesday, July, 26, 2016